Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow GENELUX Corp

Get SEC filing alerts via email and in your feed for GENELUX Corp

GNLX

GENELUX Corp

About GENELUX Corp

Genelux develops oncolytic viral immunotherapies targeting difficult-to-treat solid tumors. Its lead candidate, Olvi-Vec, is a proprietary vaccinia virus designed to selectively kill cancer cells and stimulate immune responses. The company focuses on clinical development, manufacturing, and strategic collaborations, aiming to address high unmet medical needs across multiple cancer types with off-the-shelf, personalized immunotherapies.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from GENELUX Corp

1
1
GENELUX Corp Genelux Corporation Reports $8.9 Million Net Loss in Q1 2026, No Revenue Generated

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
GENELUX Corp Genelux Corporation Reports $32.1 Million Net Loss for 2025, Focuses on Olvi-Vec Trials

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
GENELUX Corp Genelux Corporation Reports $7.95 Million Net Loss in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
GENELUX Corp Genelux Corporation Reports $7.5 Million Net Loss in Q2 2025, No Revenue Generated

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
GENELUX Corp Genelux Corporation Reports Q1 2025 Financial Results with $7.5 Million Net Loss

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
GENELUX Corp Genelux Corp. Reports $29.9 Million Net Loss for 2024 Amid Decreased Revenue

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
GENELUX Corp Genelux Corporation Reports Mixed Financial Results, Focuses on Research and Development

Via official filing (AI summary) | over 1 year ago | 0 comments